Implantable Brain Computer Interface Articles & Analysis
11 news found
Synchron, an endovascular brain-computer interface (BCI) company, today announced the first human BCI implant in the United States. ...
Synchron, an endovascular brain-computer (BCI) interface company, today announced the appointment of Kurt Haggstrom as Chief Commercial Officer. ...
Team Gleason and Synchron, an endovascular brain computer interface company, today announced a partnership agreement to provide patient-focused feedback on their platform to transform daily life for patients with physical and speech disabilities like ALS, muscular dystrophy, and cerebral palsy. ...
Synchron and Mount Sinai Hospital in New York Advance Industry-First FDA-Approved Clinical Trial for Brain-Computer Interface in U.S. Paralysis is a devastating condition for more than 5 million patients in the United States Synchron, an endovascular brain-computer (BCI) interface company, ...
Four Patients With ALS Who Received Stentrode™ Implant Gained Ability to Perform Daily Online Tasks No Serious Adverse Events Reported after 12 Months Synchron, a brain computer interface (BCI) company, today announced the results from a study in which four people with ALS received an ...
Gières (Grenoble), France, June 17, 2021 - eCential Robotics, a French growth company that designs, manufactures and markets the first unified 2D/3D robotic imaging and surgical navigation system for bone surgery indications, unveiled its surgical robotic arm as a world premiere at the annual meeting of the French Society of Spinal Surgery (SFCR), which is being held from June 17 to ...
Synchron, a brain computer interface (BCI) company, today announced the expansion of its advisory board comprised of industry pioneers, to provide strategic guidance in support of the Company’s clinical development plans, corporate strategy and growth. ...
Synchron, a brain computer interface company, today announced a Twitter takeover by Philip O’Keefe, one of the patients implanted with the Stentrode brain computer interface. ...
Synchron, a venture-backed brain data transfer company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for its flagship product, the Stentrode™ motor neuroprosthesis. This early feasibility study (EFS) of the device will begin later this year at Mount Sinai Hospital, New York, and will assess the safety ...
Additive Implants, Inc. is pleased to announce it received regulatory clearance to market in the US its second product, the SureMAX®-X Cervical Spacer. This 3D printed titanium spacer has a unique patented* design to create uniform end plate coverage and optimize load distribution. “Maximizing implant coverage of the endplates and providing for more uniform load distribution is ...
Additive Implants, Inc. is pleased to announce it received regulatory clearance to market in the US its second product, the SureMAX®-X Cervical Spacer. This 3D printed titanium spacer has a unique patented* design to create uniform end plate coverage and optimize load distribution. “Maximizing implant coverage of the endplates and providing for more uniform load distribution is ...